TY - JOUR
T1 - Imaging Dopaminergic Neurotransmission in Neurodegenerative Disorders
AU - Wallert, Elon D.
AU - Knol, Remco J. J.
AU - Beudel, Martijn
AU - de Bie, Rob M. A.
AU - Booij, Jan
AU - van de Giessen, Elsmarieke
N1 - Funding Information: Jan Booij is consultant at GE Healthcare and received research grants from GE Healthcare (all payments to the institution). Rob de Bie received research grants from GE Healthcare (paid to the institution). No other potential conflict of interest relevant to this article was reported. Publisher Copyright: COPYRIGHT © 2022 by the Society of Nuclear Medicine and Molecular Imaging
PY - 2022/6/1
Y1 - 2022/6/1
N2 - Imaging of dopaminergic transmission in neurodegenerative disorders such as Parkinson disease (PD) or dementia with Lewy bodies plays a major role in clinical practice and in clinical research. We here review the role of imaging of the nigrostriatal pathway, as well as of striatal receptors and dopamine release, in common neurodegenerative disorders in clinical practice and research. Imaging of the nigrostriatal pathway has a high diagnostic accuracy to detect nigrostriatal degeneration in disorders characterized by nigrostriatal degeneration, such as PD and dementia with Lewy bodies, and disorders of more clinical importance, namely in patients with clinically uncertain parkinsonism. Imaging of striatal dopamine D2/3 receptors is not recommended for the differential diagnosis of parkinsonian disorders in clinical practice anymore. Regarding research, recently the European Medicines Agency has qualified dopamine transporter imaging as an enrichment biomarker for clinical trials in early PD, which underlines the high diagnostic accuracy of this imaging tool and will be implemented in future trials. Also, imaging of the presynaptic dopaminergic system plays a major role in, for example, examining the extent of nigrostriatal degeneration in preclinical and premotor phases of neurodegenerative disorders and to examine subtypes of PD. Also, imaging of postsynaptic dopamine D2/3 receptors plays a role in studying, for example, the neuronal substrate of impulse control disorders in PD, as well as in measuring endogenous dopamine release to examine, for example, motor complications in the treatment of PD. Finally, novel MRI sequences as neuromelanin-sensitive MRI are promising new tools to study nigrostriatal degeneration in vivo.
AB - Imaging of dopaminergic transmission in neurodegenerative disorders such as Parkinson disease (PD) or dementia with Lewy bodies plays a major role in clinical practice and in clinical research. We here review the role of imaging of the nigrostriatal pathway, as well as of striatal receptors and dopamine release, in common neurodegenerative disorders in clinical practice and research. Imaging of the nigrostriatal pathway has a high diagnostic accuracy to detect nigrostriatal degeneration in disorders characterized by nigrostriatal degeneration, such as PD and dementia with Lewy bodies, and disorders of more clinical importance, namely in patients with clinically uncertain parkinsonism. Imaging of striatal dopamine D2/3 receptors is not recommended for the differential diagnosis of parkinsonian disorders in clinical practice anymore. Regarding research, recently the European Medicines Agency has qualified dopamine transporter imaging as an enrichment biomarker for clinical trials in early PD, which underlines the high diagnostic accuracy of this imaging tool and will be implemented in future trials. Also, imaging of the presynaptic dopaminergic system plays a major role in, for example, examining the extent of nigrostriatal degeneration in preclinical and premotor phases of neurodegenerative disorders and to examine subtypes of PD. Also, imaging of postsynaptic dopamine D2/3 receptors plays a role in studying, for example, the neuronal substrate of impulse control disorders in PD, as well as in measuring endogenous dopamine release to examine, for example, motor complications in the treatment of PD. Finally, novel MRI sequences as neuromelanin-sensitive MRI are promising new tools to study nigrostriatal degeneration in vivo.
KW - PET, SPECT
KW - Parkinson
KW - dopamine
KW - neurodegeneration
UR - http://www.scopus.com/inward/record.url?scp=85131270720&partnerID=8YFLogxK
U2 - https://doi.org/10.2967/jnumed.121.263197
DO - https://doi.org/10.2967/jnumed.121.263197
M3 - Article
C2 - 35649651
SN - 0161-5505
VL - 63
SP - 27S-32S
JO - Journal of nuclear medicine
JF - Journal of nuclear medicine
IS - 6
ER -